SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Trading Update

29 Jul 2025 07:00

RNS Number : 8873S
James Halstead PLC
29 July 2025
 

 

29 July 2025

 

 

JAMES HALSTEAD PLC (the "Company")

 

Trading Update

James Halstead plc, the commercial flooring manufacturer and international distributor, is providing the following trading update ahead of its results for the year ended 30 June 2025.

 

The Company sells, for the most part, commercial flooring across the world and has seen continued confidence in the segment of resilient sheet flooring but has experienced headwinds against sales of luxury vinyl tile (LVT) principally in Europe, the Company has however successfully managed to grow its market share in the UK. Profit before tax is in line with expectations.

 

Sales in the UK, our largest market, have improved compared to the prior financial year. Having reported that in the prior financial year there was a 5% decline versus the comparative, it is pleasing to note that our performance this year has seen this decline more than fully reverse. This is despite a degree of de-stocking by some customers, particularly those with exposure to the UK domestic carpet market.

 

Sales volumes of LVT have increased, albeit modestly, in a market segment that has seen a large decline in demand. Sales of Polyflor branded LVT products have held up due to their quality and value together with our widely accepted reputation for sustainability and environmental excellence; factors that have helped increase our market share. LVT and sheet vinyl continue to displace carpet sales in the UK market.

 

Notwithstanding this backdrop and solid UK performance, our internal expectations for the UK were higher. An anticipated uplift in demand in the education, healthcare and the prison sectors has not, yet, materialised though sales into the aged care and affordable housing sectors are performing satisfactorily.

 

In Europe, particularly in France and Holland, there has been muted activity in consumer spending which has affected refurbishment demand and new store openings in the retail sector. This has impacted LVT sales and volume declines were further compounded by increased focus of government budgets towards national security, diverting spending away from such areas as construction and social housing.

 

The products we sell are still regarded as market leading but the year has required reacting to a lower level of sales by tight cost control. In this regard, the simple model of holding stock within our distribution chain to supply demand is tried and tested around the globe.

 

In our Rest of World markets, sales have generally been more positive with very good growth, especially in the Americas, the Middle East and Mediterranean regions. Additionally, South Asia has seen the growth of recent years continue and is 38% ahead of the comparative of last year.

 

Notwithstanding the slower sales, the Group's focus on manufacturing efficiency and tight cost control of overheads have protected margins.

 

Operationally, there has been disruption to global trade routes and shipping movements with the uncertainty of tariffs on sales into the USA which has affected deliveries into many markets. However, these uncertainties have been positive regarding the sale of our UK manufactured goods into the USA, as customers seek alternative suppliers to replace products imported from countries where much higher tariffs have been imposed and with continuing uncertainly. This increased demand is despite an additional 10% duty cost to importers of our UK products.

 

In summary, the Company anticipates that sales will be marginally below the 2024 comparative with profit slightly below last year's record levels; although remaining within the range of market expectations. Cash generation alongside reserves continue to underpin an ungeared balance sheet, which remains strong.

 

The Board is confident that the prospects remain solid despite the recent external challenges and side winds.

 

The Company expects to announce its results for the year ended 30 June 2025 towards the end of September 2025.

 

 

 

 

 

Enquiries:

 

James Halstead plc

Tel: 0161 767 2500

Mark Halstead, Executive Chairman

Gordon Oliver, Chief Executive

David Drillingcourt, Finance Director

 

Hudson Sandler

Tel: 020 7796 4133

Nick Lyon / Nick Moore

Panmure Liberum (Nomad and Joint Broker)

Tel: 020 7886 2500

Ed Mansfield / Tom Scrivens

Zeus (Joint Broker)

Ben Thorne / Fraser Marshall

 

Tel: 020 3829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKFBQCBKDPOB
Date   Source Headline
9th Apr 20265:32 pmRNSGrant of Options
8th Apr 20265:19 pmRNSHolding(s) in Company
31st Mar 20267:00 amRNSInterim Results
23rd Feb 20264:48 pmRNSPDMR Acquisition of Shares
30th Jan 20263:32 pmRNSShare Buyback - Replacement
30th Jan 20262:44 pmRNSShare Buyback
29th Jan 20267:00 amRNSTrading Update
8th Jan 20268:20 amRNSBlock Listing Six Monthly Return
5th Dec 20251:00 pmRNSResult of AGM
5th Dec 20257:00 amRNSChairman’s Statement to the Annual General Meeting
14th Nov 202512:12 pmRNSDirector/PDMR Shareholding
14th Nov 202512:11 pmRNSDirector/PDMR Shareholding
17th Oct 20257:00 amRNSPosting of Annual Report and Notice of AGM
1st Oct 20257:00 amRNSPreliminary Results
8th Sep 20257:00 amRNSNotice of Preliminary Results
29th Aug 20253:55 pmRNSBLOCK LISTING SIX MONTHLY RETURN
29th Jul 20257:00 amRNSTrading Update
9th Apr 20255:32 pmRNSHolding(s) in Company
7th Apr 202512:25 pmRNSDirector/PDMR Shareholding
27th Mar 20257:00 amRNSInterim Results
6th Mar 202510:41 amRNSNotice of Interim Results - Replacement
6th Mar 20259:00 amRNSNotice of Inteirm Results
6th Mar 20257:00 amRNSNotice of Interim Results
31st Jan 20257:00 amRNSTrading Update and Notice of Results
27th Jan 20255:09 pmRNSDirector/PDMR Shareholding
6th Jan 20253:15 pmRNSBlock Listing Six Monthly Return
6th Dec 20242:09 pmRNSResults of AGM
6th Dec 20247:00 amRNSAGM Statement
18th Oct 20249:20 amRNSPosting of Annual R&A and Notice of AGM
1st Oct 20247:00 amRNSBoard Changes
1st Oct 20247:00 amRNSPreliminary Results
7th Aug 20248:05 amRNSBlock Listing Six Monthly Return
31st Jul 20247:00 amRNSTrading Update
15th Jul 20247:00 amRNSChange of Broker
8th Apr 20244:54 pmRNSPDMR Exercise of Share Options
3rd Apr 20242:00 pmRNSPDMR Acquisition of Shares
28th Mar 202412:00 pmRNSPDMR Grant of Share Options
27th Mar 20247:00 amRNSInterim Results
5th Mar 202412:30 pmRNSAppointment of Senior Independent Director
31st Jan 20247:00 amRNSTrading Update
4th Jan 20244:34 pmRNSBoard Changes
1st Dec 20232:25 pmRNSResults of Annual General Meeting
1st Dec 20237:00 amRNSAGM Statement
17th Nov 202311:13 amRNSPDMR Grant of Share Options
10th Nov 20234:45 pmRNSBlock Listing Six Monthly Return
10th Nov 20234:43 pmRNSBlock Listing Six Monthly Return
13th Oct 202312:00 pmRNSPosting of Annual R&A and Notice of AGM
2nd Oct 20237:00 amRNSPreliminary Results
1st Aug 20237:00 amRNSTrading Update
31st Mar 20231:57 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.